BARD PERIPHERAL VASCULAR, INC.

BARD PERIPHERAL VASCULAR, INC. specializes in the design, manufacture, and supply of advanced vascular surgical implants and medical devices, with deep expertise in peripheral vascular stents, vascular grafts, and implantable prosthetic systems. The company’s technical capabilities center on minimally invasive interventional devices, including drug-eluting stents, venous stent platforms, and customized vascular implant solutions tailored for endovascular procedures. Their products support complex vascular interventions, emphasizing biocompatibility, long-term patency, and precision delivery systems. The firm demonstrates consistent innovation in endovascular therapy, with a focus on devices that address atherosclerotic disease, venous insufficiency, and occlusive vascular conditions. The contractor maintains a primary relationship with the Department of Veterans Affairs, supplying critical vascular implants and surgical prosthetics to VA medical centers nationwide. These procurements support veteran-specific care pathways, including revascularization, limb salvage, and post-traumatic vascular reconstruction. The Department of Health and Human Services also engages the contractor for specialized surgical appliance needs, reflecting alignment with federal health equity and chronic disease management initiatives. Industry focus is concentrated in NAICS 339113 (Surgical Appliance and Supplies Manufacturing) and 339112 (Surgical and Medical Instrument Manufacturing), where the company operates as a niche supplier of Class II and Class III medical devices under FDA regulatory frameworks. Their market positioning is defined by high-complexity, low-volume vascular implants requiring stringent quality control, sterilization protocols, and traceability systems compliant with ISO 13485 standards. As a 2L entity headquartered in Tempe, Arizona, BARD PERIPHERAL VASCULAR, INC. operates as a specialized manufacturer without federal small business certifications. The company’s geographic footprint supports national distribution of implantable vascular systems, with operations calibrated to meet the demands of federal healthcare procurement cycles and just-in-time delivery requirements for critical care settings.